The predominant mode of transmission of SARS-CoV-2 virus and coronavirus disease 2019 (COVID-19) is aerosols, and e-cigarettes/vaping products are a source of aerosols. There is a public health concern that the use of these products may increase the risk of COVID-19 transmission, susceptibility to COVID-19 and severity of the disease. Based on a review of existing literature, we found emerging evidence that suggests that people who vape are at higher risk of COVID-19, and, because of compromised lung function, their susceptibility to the disease and the severity of outcomes is increased. Aerosols generated by vaping products could be involved in the transmission of the virus when people are close to others who have been diagnosed with COVID-19 and are vaping. These findings may be useful to health care professionals, including dental professionals, in providing evidence to support informing patients about vaping and how the use of vaping products impacts the risk of COVID-19 transmission, infection susceptibility and severity of illness.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Background: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics.
Analysis of related factors for systemic lupus erythematosus flare after SARS-Cov-2 infection: A retrospective cohort study.
Int J Rheum Dis
January 2025
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Objective: Since COVID-19 infections are more common in systemic lupus erythematosus (SLE) patients, most recent research has focused on the outcome of COVID-19, with fewer studies on disease activity in SLE. This research aims to evaluate flares in SLE with COVID-19 infection while investigating predictive factors.
Methods: A questionnaire survey was conducted to collect information on patients with previously diagnosed SLE from multi-center.
Antidiabetic agent use and clinical outcomes in patients with diabetes hospitalized for COVID-19: a systematic review and meta-analysis.
Front Endocrinol (Lausanne)
January 2025
Boston College, William F. Connell School of Nursing, Boston, MA, United States.
Background: The effect of antidiabetic agents on mortality outcomes is unclear for individuals with diabetes mellitus (DM) who are hospitalized for COVID-19.
Purpose: To examine the relationship between antidiabetic agent use and clinical outcomes in individuals with DM hospitalized for COVID-19.
Methods: A systematic review of the literature (2020-2024) was performed across five databases.
Gameplay and physical activity behaviors in adult video game players.
Front Sports Act Living
January 2025
Department of Kinesiology, Texas Christian University, Fort Worth, TX, United States.
Introduction: Since the early 2000s, the video game industry has seen extraordinary booms in product development and market growth, with the total number of video game players globally reaching 2.69 billion by the end of 2020. Despite the rapid growth of the industry, there is little recent data investigating the time adult video game players spend sedentary playing video games and the time they spent engaged in physical activity.
View Article and Find Full Text PDFClinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study.
Front Neurol
January 2025
Unidade Local de Saúde de São João, Porto, Portugal.
Background: Anti-CD20 monoclonal antibodies are a class of immunosuppressive drugs widely used in the treatment of central nervous system (CNS) inflammatory diseases, with well-established efficacy and safety. Although rare, these therapies can be associated with serious adverse events including hematological and infectious complications. This study aims to evaluate their safety and tolerability profile in real-world clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!